Tengion Inc

Tengion — Investor Day (October 2010)

63 slides from Tengion's investor day presentation, Oct 27, 2010

  1. Slide 1: Tengion Analyst & Investor Meeting

    Exhibit 99.1 Tengion Analyst & Investor Meeting October 27, 2010 1

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements Certain statements in this presentation may constitute forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Although Tengion believes that these statements are based upon reasonable assumptions within the bounds of its know

  3. Slide 3: Agenda

    Agenda Company Overview Steven Nichtberger, MD, President and CEO Tengion’s Regenerative Medicine Platform and Product Development Pathway Tim Bertram, DVM, PhD - Executive Vice President Science & Technology and Chief Scientific Officer Neo-Urinary Conduit - Clinical Sunita Sheth, MD, Chief Medical

  4. Slide 4: Company Highlights

    Company Highlights Tengion products harness the body’s natural ability to regenerate § Unique and productive research platform Lead clinical product targets patients with bladder cancer § First patient enrolled, biopsied and implanted successfully – 1 quarter later than anticipated § Investigators a

  5. Slide 5: Catalyzing Regeneration in the Body

    Catalyzing Regeneration in the Body Humans have limited capacity to regenerate Our platform uniquely catalyzes human tissue regeneration Cells Biomaterials INTEGRATED PLATFORM Industrialization Implantation 5

  6. Slide 6: Tengion Product Pipeline

    Tengion Product Pipeline Optimization Preclinical IND Phase! Phase Il Phase Il Lead Platform Programs Neo-Urinary Conduit Bladder Cancer Neo-Kidney Augment Advanced CKO mm Neo-GI Augment Eophagectony — Additional Platform Programs Neo-Bladder Replacement Cystectomy __| Neo-Bladder Augment Spina Bifi

  7. Slide 7: Tengion's Regenerative Medicine Platform and Product Development Pathway

    Tengion’s Regenerative Medicine Platform and Product Development Pathway Tim Bertram, DVM, PhD 7

  8. Slide 8: Accelerated Product Development Pathway

    Accelerated Product Development Pathway Translation of Regenerative Medicine Products § Product-directed scientists addressing unmet medical need § Optimized product formulation for optimal outcomes § Established development pathway to commercialization § Scale-up manufacturing to meet market demand

  9. Slide 9: Platform - Cells

    Cells Biomaterials Platform - Cells INTEGRATED PLATFORM Defined regenerative cells taken from the patient Industrialization § Autologous cells – Identify, characterize and expand selected regenerative cells – Indifferent as to tissue source or cell type - focus is optimizing regeneration – Avoids ri

  10. Slide 10: Platform - Biomaterials

    Cells Biomaterials Platform - Biomaterials INTEGRATED PLATFORM Biomaterials for enhancing formulation and outcomes Industrialization § Focus on materials with clinical precedent to support regeneration § Optimize formulation for maximal product stability Conduit: Bladder cancer patients requiring bl

  11. Slide 11: Platform - Industrialization

    Cells Biomaterials Platform - Industrialization INTEGRATED PLATFORM GMP compliant scale-up and focus on cost of goods Industrialization § Integrated, GMP-compliant processing, bio-analytical methods and delivery devices to produce scalable, cost-efficient products Conduit: Bladder cancer patients re

  12. Slide 12: Platform - Implantation

    Cells Biomaterials Platform - Implantation INTEGRATED PLATFORM 3-Dimensional tissue and organ regeneration Industrialization § Key opinion leaders have performed preclinical surgeries to inform product design § Implant procedure being standardized for consistent outcomes Conduit: Bladder cancer pati

  13. Slide 13: Regulatory Pathway - Combination Products

    Regulatory Pathway - Combination Products CBER lead with CDRH collaboration Conduit: Bladder cancer patients requiring bladder removal § BLA with CBER in the lead and CDRH collaborating § IND accepted in 30 days § Neo-Bladder Augment experience in US and Europe is instructive for conduit Kidney Augm

  14. Slide 14: IP and Barriers to Entry

    IP and Barriers to Entry Issued patent protection to 2021, plus recent applications pending § 37 US and 130 international patents and patent applications § Core patents cover composition, design and methods of manufacture* Urologic Neo-Kidney Franchise Augment DEVICE / CELLS DEVICE / CELLS MATERIAL

  15. Slide 15: Neo-Urinary Conduit Clinical Update

    Neo-Urinary Conduit Clinical Update Sunita Sheth, MD 15

  16. Slide 16: Tengion Product Pipeline

    Tengion Product Pipeline Optimization Preclinical IND Phase! Phase ll Phase I Lead Platform Programs Neo-Urinary Conduit Bladder Cancer Neo-Kidney Augment Neo-GI Augment Esaphagectony — Additional Platform Programs Neo-Bladder Replacement Cystectomy a Neo-Bladder Augment Spine Bie LL Spinal Cord Inj

  17. Slide 17: Bladder Cancer Management

    Bladder Cancer Management Urinary diversion procedures When bladder removal is needed, a urinary diversion procedure is performed… Orthotopic Neo-bladder (1,600 annually in the US & EU) § Native bladder removed § Section of bowel isolated, with blood supply maintained § Bowel continuity re-establish

  18. Slide 18: Current Standard of Care - Common Side Effects

    Current Standard of Care - Common Side Effects Bowel Complications Mucus Secretion Leaks, fistulas, obstructions, anemia Bowel tissue secretes and neurological abnormalities mucus into urine Cancer Stone Formation Malignancy may result from Recurrent stones in ~10% use of bowel tissue of conduit pat

  19. Slide 19: Neo-Urinary Conduit

    Neo-Urinary Conduit Expanding an established regeneration technology platform SMC from Adipose Scaffold Construct Surgical Implantation In vivo Regeneration Urinary diversion Neo-Urinary Conduit 19

  20. Slide 20: Neo-Urinary Conduit Clinical trial

    Neo-Urinary Conduit Clinical trial Open label study to define surgical procedure and safety profile § 5 patients with primary bladder cancer requiring bladder removal – U of Chicago and Johns Hopkins screening § Selective enrollment criteria – Bladder cancer, stage T1/T2 and N0, M0 only – Not obese

  21. Slide 21: Neo-Urinary Conduit Trial

    Neo-Urinary Conduit Trial Incorporating years of clinical development experience Selected entry criteria for initial clinical study § Enroll a less complicated and more homogeneous population – Minimize risk of unrelated events Standardize surgical approach and post-op stoma care § Same 2 surgeons a

  22. Slide 22: Neo-Urinary Conduit Enrollment

    Neo-Urinary Conduit Enrollment First patient has been implanted at U of Chicago § Biopsied, manufactured product to specifications, shipped, implanted § 1 quarter longer than anticipated to identify first patient Investigators expect more timely enrollment going forward § First patient with Neo-Urin

  23. Slide 23: Neo-Urinary Conduit Commercial Opportunity

    Neo-Urinary Conduit Commercial Opportunity Mark Stejbach 23

  24. Slide 24: Conduit Commercial Opportunity

    Conduit Commercial Opportunity Efficacy without the morbidity of using bowel Compelling potential advantages across stakeholders § Eliminates need to harvest bowel from the patient § May reduce / eliminate many acute and chronic complications § Value proposition driven by targeted safety profile 13,

  25. Slide 25: Cystectomy Procedures (IMS 2005-6)

    Cystectomy Procedures (IMS 2005-6) Provides a sound basis for current market assumptions ICD-9 Code Description Procedures 57.71 Radical Cystectomy 12,778 Today, these patients get either a conduit or a bladder replacement created from their own gastrointestinal tissue ~15% of Conduits are placed fo

  26. Slide 26: If this works, why would I ever do the traditional procedure?

    “If this works, why would I ever do the traditional procedure?” Most Important Importance Rankings Least Important BASE: Total physicians performing cystectomies, n=204) PPQ1. What advantages, if any, do these products have over existing options? BioVid survey, Jul 08 26

  27. Slide 27: Market Research Reinforces Rapid Uptake Expectations

    Market Research Reinforces Rapid Uptake Expectations Based on the product profile, urologists were asked to rate the Neo-Urinary Conduit compared to the standard of care Percent of Very advantageous respondents Advantageous 52% 45% 3% No difference Disadvantageous Very Disadvantageous 0% 20% 40% 60%

  28. Slide 28: US Commercial Strategy

    US Commercial Strategy Fully accessible market internally or through partnering Direct Sales Force § Sequenced product launches through centers of excellence § >65% of market covered by a specialty sales force of ~ 20 reps Commercial Model § Certified urologist requests biopsy kit § Reimbursement co

  29. Slide 29: Conduit Commercial Assessment

    Conduit Commercial Assessment Summary Most of the 24,000 US / EU annual conduit procedures are for bladder cancer Market uptake driven by elimination of bowel surgery § Market research with urologists is unambiguous § Potential for acute and chronic benefits § Potential for new standard of care by e

  30. Slide 30: Neo-Kidney Augment Preclinical Research

    Neo-Kidney Augment Preclinical Research Sharon Presnell, PhD 30

  31. Slide 31: Neo-Kidney Augment (NKA) Overview

    Neo-Kidney Augment (NKA) Overview Intended to delay the need for dialysis or transplantation 100,000 new dialysis patients each year in the US § 350,000 currently on dialysis § 20% annual mortality § $60,000 1st year cost per patient § $22 billion in direct US costs annually for end stage kidney dis

  32. Slide 32: Neo-Kidney Augment Preclinical Research Summary

    Neo-Kidney Augment Preclinical Research Summary Proof-of-concept established for regenerative renal cells in three independent small animal models of chronic kidney disease (CKD) § 5/6 Nephrectomy model of terminal renal insufficiency* § ZSF1 model of metabolic syndrome and diabetic nephropathy** §

  33. Slide 33: Neo-Kidney Augment Preclinical Research Summary

    Neo-Kidney Augment Preclinical Research Summary Proof-of-concept established for regenerative renal cells in three independent small animal models of chronic kidney disease (CKD) § 5/6 Nephrectomy model of terminal renal insufficiency* § ZSF1 model of metabolic syndrome and diabetic nephropathy** §

  34. Slide 34: 5/6 Nephrectomy Model of CKD

    5/6 Nephrectomy Model of CKD Renal disease secondary to reduced kidney mass Terminal progressive renal failure § 0% survival at 6M post-nephrectomy § Progressive decline in GFR Rodent 5/6 Nx-induced § Uremic model of renal failure § Anemic § Proteinuria § Hypertensive § Weight loss § Progressive glo

  35. Slide 35: Renal Cell Function Validated in vivo

    Renal Cell function Validated in vivo In rodent 5/6 nephrectomy model of chronic renal failure NKA Renal cells delivered after chronic SHAM disease state established NX § sCREAT sustained at >200% § BUN sustained at >150% NKA Selected regenerative renal cells (NKA) outperform unfractionated HEALTHY

  36. Slide 36: Neo-Kidney Augment Preclinical Research Summary

    Neo-Kidney Augment Preclinical Research Summary Proof-of-concept established for regenerative renal cells in three independent small animal models of chronic kidney disease (CKD) § 5/6 Nephrectomy model of terminal renal insufficiency* § ZSF1 model of metabolic syndrome and diabetic nephropathy** §

  37. Slide 37: Obese ZSF1 Rats Model Progressive Nephropathy

    Obese ZSF1 Rats Model Progressive Nephropathy Renal disease secondary to diabetes mellitus and hypertension Aggressive Metabolic Syndrome § Morbid obesity (leptin-receptor deficient) § ~50% mortality at ~1yr § Multiple co-morbid conditions – Hyperglycemia – Vasculopathy ZSF1 rodent model of – Hypert

  38. Slide 38: Validating Renal Cells in Chronic Disease

    Validating Renal Cells in Chronic Disease Renal failure secondary to obesity and Type 2 diabetes (ZSF1) STABLE CKD 3 CKD 4 DECLINE CKD 5 FAILURE Intervention windows: § Stage 3 CKD with no control of hyperglycemia § Stage 4 CKD with moderate control of hyperglycemia § Stage 5 CKD with moderate contr

  39. Slide 39: Renal Cells Improved Function Throughout the Nephron

    Renal Cells Improved Function Throughout the Nephron Glomeruli, tubules and collecting ducts Untreated OB ZSF1 + At > 1 year of age: NKA § 35% improvement in eGFR (Filtration) § 15% reduction in phosphatemia * (Tubular Function) p= § 10% improvement in uOSM 0.033 (Concentration) Deaths in untreated

  40. Slide 40: Renal Cells Reduced Hypertension and Improved Survival

    Renal Cells Reduced Hypertension and Improved Survival ZSF1 rats at >1 year of age p= 0.042 § Renal Cells reduced mean arterial blood pressure (MABP) significantly Treatment 63-week § Renal Cells support survival Group Survival beyond 50% mortality time point for OB ZSF1 Untreated 20% OB ZSF1 (1/5)

  41. Slide 41: Neo-Kidney Augment Preclinical Research Summary

    Neo-Kidney Augment Preclinical Research Summary Proof-of-concept established for regenerative renal cells in three independent small animal models of chronic kidney disease (CKD) § 5/6 Nephrectomy model of terminal renal insufficiency* § ZSF1 model of metabolic syndrome and diabetic nephropathy** §

  42. Slide 42: Nude Rat Model of CKD

    Nude Rat Model of CKD Enables functional assessment of bioactive human cells Chronic renal insufficiency § Renal failure due to Ischemia- Reperfusion + Gentamicin (I-R/G) § Rats that fail to recover 3M post-injury Rodent model of CKD are utilized (chronic after acute) after acute injury § Model char

  43. Slide 43: Human Kidney Tissue Regeneration in Nude Rats

    Human Kidney Tissue Regeneration in Nude Rats Delayed progression of CKD and stabilized renal function Treatment Human-derived cells I-R/G Injury prevent renal failure in I-R/G Injury + CKD Nude Rats for 3 mo. Human Renal Cells * * 1 4 12 * p<0.05 weeks post- treatment Human-derived cells improve CK

  44. Slide 44: Neo-Kidney Augment Preclinical Research Summary

    Neo-Kidney Augment Preclinical Research Summary Proof-of-concept established for regenerative renal cells in three independent small animal models of chronic kidney disease (CKD) § 5/6 Nephrectomy model of terminal renal insufficiency* § ZSF1 model of metabolic syndrome and diabetic nephropathy** §

  45. Slide 45: Modified 5/6 Nephrectomy Canine Model of CKD

    Modified 5/6 Nephrectomy Canine Model of CKD Renal disease secondary to reduced kidney mass Chronic renal insufficiency § >50% reduction in GFR § Mild hypertension Canine 5/6 Nx-induced § Uremia model of renal failure § Mild anemia § Progressive proteinuria § Gradual weight loss STEP STEP 1 2 INTACT

  46. Slide 46: Renal Cell Delivery Verified

    Renal Cell Delivery Verified In dogs with single kidney (n=2) No adverse events No systemic evidence Caudal Renal Caudal of renal injury Pole PoleRenal Injected Exposed NKA Product § Serum chemistry Normal histology (1M R-Kidney L-Kidney post-implant) (Control), 40x (NKA), 40x L-Kidney (NKA), 40x L-

  47. Slide 47: POC Study Indicates Renal Cells Improve Function

    POC Study Indicates Renal! CellSimprovexstas In 5/6-Nephrectomized dog Mode) AttiTCE NTO nia ACTIN s)) 400% 5/6 NX, UNTREATED (n=2) 5/6 NX + NKA (n=2) ¢ 300% 4 Treatment with Renal Cells 2 200% SASELNE 1 shows trends of efficacy: 7 GFR = 0.55 (mltnitvkg) ° OQ 100% (CKD Stage 4) fee = /ncreased Creat

  48. Slide 48: Follow-Up Study Confirms Renal Cell Function

    Renal filtration < balance improv treatment (p = 0. Treatment prom vs. weight loss ( *Multivariable linear regression using ‘Treatment’, ‘Age’, and ‘Animal’ to predict UPC and Body Weight. P values = Effects Test for Treatment. Active Study, planned for 6 months Relative UPC Ratio Relative Body Weig

  49. Slide 49: Neo-Kidney Augment Preclinical Research Summary

    Neo-Kidney Augment Preclinical Research Summary Proof-of-concept established for regenerative renal cells in three independent small animal models of chronic kidney disease (CKD) § 5/6 Nephrectomy model of terminal renal insufficiency* § ZSF1 model of metabolic syndrome and diabetic nephropathy** §

  50. Slide 50: Human Translation of Cellular Components

    Human Translation of Cellular Components Isolation, characterization and expansion from diseased human kidney § Standard core needle biopsy procedure § (0.02g tissue) Cells can be expanded and cryopreserved § Salient phenotypic attributes are preserved § Supports autologous sourcing strategy Presnel

  51. Slide 51: Validation of Renal Cell Function in Four Models

    Validation of Renal Cell Function in Four Models Increases probability of success through development 1. Renal cells demonstrated durable function in 5/6 Nx rodent model of CKD due to renal mass insufficiency* § Robust therapeutic effect (animals followed 6M post-implant) § Reproducible across indep

  52. Slide 52: Neo-Kidney Augment Research to Clinic

    Neo-Kidney Augment Research to Clinic Deepak Jain, PhD 52

  53. Slide 53: Neo-Kidney Augment: Research to clinic

    Cells Biomaterials Neo-Kidney Augment INTEGRATED PLATFORM Research to clinic Industrialization Cells Biomaterials Selected Regenerative Product Cells Formulation INTEGRATED PLATFORM Industrialization Implantation Manufacturing/Product Product Release Delivery 53

  54. Slide 54: Neo-Kidney Augment: Cells

    Cells Biomaterials Neo-Kidney Augment INTEGRATED PLATFORM Cells: selected regenerative cell sourcing Industrialization Cell Sourcing § Kidney needle biopsy Cell Isolation § Enzyme digestion of biopsy § Cell washing and plating Tissue Culture Flasks Cell Expansion § By serial passage COBE § Separated

  55. Slide 55: Neo-Kidney Augment: Biomaterials

    Cells Biomaterials Neo-Kidney Augment INTEGRATED PLATFORM Biomaterials: product formulations Industrialization Renal Cell - Biomaterial Formulations Neo-Kidney Augment Program Selected Regenerative Renal Cell Population § Demonstrated efficacy Biomaterial Formulation Provides § Cell stability and du

  56. Slide 56: Neo-Kidney Augment: Industrialization

    Cells Biomaterials Neo-Kidney Augment INTEGRATED PLATFORM Industrialization: manufacturing Industrialization Manufacturing: Product Characterization and § Closed system Quality Release Criteria: – aseptic, scalable manufacturing § Maintain integrity during transport § User-friendly handling in the O

  57. Slide 57: Neo-Kidney Augment: Implantation

    Cells Biomaterials Neo-Kidney Augment INTEGRATED PLATFORM Implantation: Product Delivery Industrialization Delivery of Injectable Product: § Syringe and needle § Catheter Product Implantation: § Effective delivery 57

  58. Slide 58: Neo-Kidney Augment Clinical Development Considerations

    Neo-Kidney Augment Clinical Development Considerations Sunita Sheth, MD 58

  59. Slide 59: Chronic Kidney Disease Affects Over 20 million in US

    Chronic Kidney Disease Affects Over 20 million in US Expected to double by 2020, driven by diabetes CKD Prevalence by Primary Diagnosis at (000s) Stage ESRD Diabetes 4% 1% Hypertension 13% 1% Glomerulonephritis 2% 44% 7% Cystic Kidney Disease Urologic Disease Other 28% known Unknown Missing data Sou

  60. Slide 60: Clinical Development Pathway

    Clinical Development Pathway Informed by preclinical studies and regulatory history Clinical Benefit § Improve kidney function in patients at risk of requiring dialysis § Delay progression of kidney failure or time to onset of dialysis Target Population § Stage of kidney failure – Stage 3 and 4 § Un

  61. Slide 61: Conclusions

    Conclusions Neo-Urinary Conduit Trial in Bladder Cancer Patients § Successful first implant – Biopsy, manufacturing, quality release and implant procedure § Investigators optimistic regarding future enrollment timelines – First patient successfully implanted – Two sites actively screening § Anticipa

  62. Slide 62: 62

    62

  63. Slide 63: Slide 63

Tengion — Investor Day (October 2010) on 6ix